Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sonnet Biotherapeutics Holdings Inc SONN

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.


NDAQ:SONN - Post by User

Comment by Iseneschalon Oct 31, 2022 12:31pm
52 Views
Post# 35060410

RE:RE:SONN ..... Sorry Folks.... Can't please everyone ; )

RE:RE:SONN ..... Sorry Folks.... Can't please everyone ; )
Chefboy69 wrote: WEED 

called it bro...lol


You're turning this into a "pissing match".......LMFAO

WEED.....LoL
Canopy Growth loses $2.08-billion in fiscal Q1

2022-08-05 06:22 ET - News Release

 

Mr. David Klein reports

CANOPY GROWTH CORPORATION REPORTS FIRST QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS

Canopy Growth Corp. has released its financial results for the first quarter ended June 30, 2022.

Highlights:

 

  • Q1 fiscal 2023 net revenue was flat compared with Q4 fiscal 2022;
  • Company maintained No. 1 share of combined premium flower and prerolled joint (PRJ) segment in Q1 fiscal 2023;
  • Increased share of the combined mainstream flower and PRJ segment by 35 basis points to 4.0 per cent in Q1 fiscal 2023;
  • International medical cannabis net revenue approximately doubled versus Q1 fiscal 2022, driven primarily by strong sales in Israel and Australia;
  • Record BioSteel revenues in Q1 fiscal 2023 increased 169 per cent versus Q1 fiscal 2022;
  • Secured retail agreement with Walmart stores covering 2,200 stores in 39 states;
  • Entered partnership to become the official hydration partner of the NHL (National Hockey League) and NHLPA (National Hockey League Players' Association);
  • Cost reduction program on track with operating expenses in Q1 fiscal 2023 decreasing by 13 per cent versus Q1 fiscal 2022

<< Previous
Bullboard Posts
Next >>